Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03652064
Title A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

multiple myeloma

Therapies

Bortezomib + Dexamethasone + Lenalidomide

Bortezomib + Daratumumab + Dexamethasone + Lenalidomide

Dexamethasone + Lenalidomide

Daratumumab + Dexamethasone + Lenalidomide

Age Groups: senior | adult
Covered Countries USA | FRA | ESP | DEU | CAN


No variant requirements are available.